Lyell Immunopharma, Inc.
LYEL
$22.31
$1.507.21%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -34.92% | 11.11% | -4.41% | -53.08% | -99.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.92% | 11.11% | -4.41% | -53.08% | -99.87% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -34.92% | 11.11% | -4.41% | -53.08% | -99.87% |
| SG&A Expenses | -3.25% | -7.90% | -14.06% | -22.31% | -36.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -48.52% | -42.42% | -49.57% | -31.64% | -15.57% |
| Total Operating Expenses | -8.45% | -6.03% | -8.23% | -11.07% | -13.58% |
| Operating Income | 8.44% | 6.03% | 8.23% | 11.05% | -7.11% |
| Income Before Tax | -59.65% | -57.61% | -46.50% | -46.18% | -7.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -59.65% | -57.61% | -46.50% | -46.18% | -7.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.65% | -57.61% | -46.50% | -46.18% | -7.31% |
| EBIT | 8.44% | 6.03% | 8.23% | 11.05% | -7.11% |
| EBITDA | 6.50% | 4.77% | 7.99% | 11.76% | -8.22% |
| EPS Basic | -38.91% | -42.31% | -34.24% | -36.58% | -5.48% |
| Normalized Basic EPS | 19.00% | 13.30% | 14.21% | 15.20% | -6.59% |
| EPS Diluted | -38.91% | -42.31% | -34.24% | -36.58% | -5.48% |
| Normalized Diluted EPS | 19.00% | 13.30% | 14.21% | 15.20% | -6.59% |
| Average Basic Shares Outstanding | 21.35% | 11.19% | 7.75% | 4.18% | 1.82% |
| Average Diluted Shares Outstanding | 21.35% | 11.19% | 7.75% | 4.18% | 1.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |